Harvard Bioscience Statistics
Total Valuation
HBIO has a market cap or net worth of $30.30 million. The enterprise value is $68.00 million.
| Market Cap | 30.30M |
| Enterprise Value | 68.00M |
Important Dates
The last earnings date was Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HBIO has 4.55 million shares outstanding. The number of shares has increased by 1.81% in one year.
| Current Share Class | 4.55M |
| Shares Outstanding | 4.55M |
| Shares Change (YoY) | +1.81% |
| Shares Change (QoQ) | +1.18% |
| Owned by Insiders (%) | 7.12% |
| Owned by Institutions (%) | 29.92% |
| Float | 3.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 36.97 |
| PS Ratio | 0.35 |
| Forward PS | 0.33 |
| PB Ratio | 4.08 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 46.54 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.77 |
| EV / EBITDA | 9.23 |
| EV / EBIT | 34.50 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.87, with a Debt / Equity ratio of 5.96.
| Current Ratio | 1.87 |
| Quick Ratio | 0.85 |
| Debt / Equity | 5.96 |
| Debt / EBITDA | 4.52 |
| Debt / FCF | n/a |
| Interest Coverage | 0.30 |
Financial Efficiency
Return on equity (ROE) is -89.95% and return on invested capital (ROIC) is 2.23%.
| Return on Equity (ROE) | -89.95% |
| Return on Assets (ROA) | 1.58% |
| Return on Invested Capital (ROIC) | 2.23% |
| Return on Capital Employed (ROCE) | 3.83% |
| Weighted Average Cost of Capital (WACC) | 11.96% |
| Revenue Per Employee | $259,021 |
| Profits Per Employee | -$30,714 |
| Employee Count | 339 |
| Asset Turnover | 1.12 |
| Inventory Turnover | 1.65 |
Taxes
| Income Tax | -129,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +33.10% in the last 52 weeks. The beta is 1.49, so HBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.49 |
| 52-Week Price Change | +33.10% |
| 50-Day Moving Average | 6.17 |
| 200-Day Moving Average | 6.05 |
| Relative Strength Index (RSI) | 61.09 |
| Average Volume (20 Days) | 16,786 |
Short Selling Information
The latest short interest is 61,370, so 1.35% of the outstanding shares have been sold short.
| Short Interest | 61,370 |
| Short Previous Month | 56,015 |
| Short % of Shares Out | 1.35% |
| Short % of Float | 1.73% |
| Short Ratio (days to cover) | 4.80 |
Income Statement
In the last 12 months, HBIO had revenue of $87.81 million and -$10.41 million in losses. Loss per share was -$2.35.
| Revenue | 87.81M |
| Gross Profit | 51.07M |
| Operating Income | 1.97M |
| Pretax Income | -10.54M |
| Net Income | -10.41M |
| EBITDA | 7.37M |
| EBIT | 1.97M |
| Loss Per Share | -$2.35 |
Balance Sheet
The company has $6.50 million in cash and $44.21 million in debt, with a net cash position of -$37.70 million or -$8.28 per share.
| Cash & Cash Equivalents | 6.50M |
| Total Debt | 44.21M |
| Net Cash | -37.70M |
| Net Cash Per Share | -$8.28 |
| Equity (Book Value) | 7.42M |
| Book Value Per Share | 1.63 |
| Working Capital | 21.67M |
Cash Flow
In the last 12 months, operating cash flow was $651,000 and capital expenditures -$1.77 million, giving a free cash flow of -$1.12 million.
| Operating Cash Flow | 651,000 |
| Capital Expenditures | -1.77M |
| Depreciation & Amortization | 5.40M |
| Net Borrowing | 4.65M |
| Free Cash Flow | -1.12M |
| FCF Per Share | -$0.25 |
Margins
Gross margin is 58.16%, with operating and profit margins of 2.24% and -11.86%.
| Gross Margin | 58.16% |
| Operating Margin | 2.24% |
| Pretax Margin | -12.00% |
| Profit Margin | -11.86% |
| EBITDA Margin | 8.39% |
| EBIT Margin | 2.24% |
| FCF Margin | n/a |
Dividends & Yields
HBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.81% |
| Shareholder Yield | -1.81% |
| Earnings Yield | -34.37% |
| FCF Yield | -3.69% |
Analyst Forecast
The average price target for HBIO is $7.50, which is 12.70% higher than the current price. The consensus rating is "Hold".
| Price Target | $7.50 |
| Price Target Difference | 12.70% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 16, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 16, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
HBIO has an Altman Z-Score of -2.26 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.26 |
| Piotroski F-Score | 6 |